Retigabine, a KV7 (KCNQ) potassium channel opener, attenuates l-DOPA-induced dyskinesias in 6-OHDA-lesioned rats
paradigm_report_works_22122023
10.1016_j.neuropharm.2011.10.016
23
2
2011
1052
1061
article
62
Neuropharmacology
Elsevier BV
Svenja E. Sander
Carol A. Lemm
Naomi F. Lange
Melanie Hamann
A. Richter
False
10.1016/j.neuropharm.2011.10.016
Retigabine, a KV7 (KCNQ) potassium channel opener, attenuates l-DOPA-induced dyskinesias in 6-OHDA-lesioned rats
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our
Terms of Service and Privacy Policy.